CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00168740
NCT00168740Phase 3Completed
CompareCT.gov

Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma

Biogen·interventional·Posted Sep 15, 2005·Updated Sep 15, 2005

In Brief

A Phase 3 clinical trial evaluating rituximab for Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma. Completed, across 31 sites in 2 countries.

Detailed Summary

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLow-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartApr 1, 1995
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

rituximabdrug